Half Year 2026 Idorsia Ltd Earnings Call Transcript

Jul 30, 2026 / 12:00 PM GMT

Release Date Price: $8

Transcript

Key Points

Positve

QUVIVIQ sales surged 62% year-over-year to CHF 91 million in H1 2026, driven by strong commercial momentum in Europe and Canada, with the US returning to growth.
The company significantly strengthened its financial position by refinancing a short-term facility with a long-term CHF 147 million term loan from Pharmacom, extending maturity to June 2031 and providing total liquidity of CHF 189 million.
Positive Phase 2 results for daridorexant in pediatric insomnia, including children with neurodevelopmental disorders, demonstrated statistically significant efficacy and a favorable safety profile, opening a potential new indication.
The pipeline is advancing with multiple value inflection points, including the initiation of a pivotal kidney biopsy study for lucerastat in Fabry disease and completed recruitment for the CCR6 antagonist psoriasis study.
Strategic partnerships, including new co-promotion agreements with Menarini and Viatris, are expanding QUVIVIQ's reach into primary care and new geographic markets, such as Italy and Canada.
The company is exploring a dedicated financing structure for Aprocitentan (TRIVIO/JEREGO) backed by existing SPV investors, which would fund its launch without allocating capital from Idorsia's core operations.

Negative

The company still reported a non-GAAP EBIT loss of CHF 54 million in H1 2026, indicating ongoing operational losses despite revenue growth.
The US commercial strategy is still in a transformation phase, with the direct-to-patient (DTP) model only at the pilot stage and its impact on growth and profitability yet to be proven.
The financing and co-promotion structure for Aprocitentan is still under negotiation, with no binding terms or magnitude of investment disclosed, creating uncertainty around the launch timeline.
The company has significant debt obligations, including a CHF 250 million convertible loan to J&J that can be converted at any time, potentially leading to future dilution.
Several key pipeline programs, such as the CXCR7 antagonist for MS and the CXCR3 antagonist for vitiligo, are still in early-stage development with results not expected until 2028 or later, carrying high clinical risk.
The company's cash runway only extends into 2028, and it will need to achieve its commercial and pipeline milestones to avoid future financing needs or additional dilution.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

IDIA.S - Idorsia Ltd
Half Year 2026 Idorsia Ltd Earnings Call
Jul 30, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon or good morning, everyone, and welcome to our half-year 2026 investor webcast. My name is Kevin Boss, and I'm responsible for investor relations at Idorsia. Today, rather than simply reviewing what happened during the first six months of the year, we want to focus on what will drive the next phase of growth and value creation at Idorsia.

Joining me on the call. We have Jean-Paul Clausel, Chairman and Interim CEO Benjamin Limal, Head of Europe and International Markets Shal Jakobowitz, President of Idorsia US Martin Clausel, Chief Scientific Officer and Head of Research Dominique Leterrier, Global Commercial Strategy and New Product Planning Amer Joseph, Chief Medical Officer and Head of Global Clinical Development and Arno

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.